Skip to main content

Table 4 Summary of mutation analysis

From: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Gene No. of patients No. of mutations %
KRAS 32 1 3
BRAF 32 0 0
CDH1 22 2 9